RTB-101 is a catalytic inhibitor of mTOR and other kinases, biochemically similar to taurine.

“and also it has a shorter half-life it's half-life is four to six hours so if you dose it once a day it's inhibiting torque 1 for a shorter period of time than at verilyminus and if you give it twice a day it's a little bit more persistent inhibition”

“so there's two mtor complexes that contain mtor and this is most potent inhibitor of the torque one complex”

“rtb 101 the drug we talked about previously in the the restore bio phase three clinical trial is a catalytic inhibitor of mtor as well as other kinases so it would fall at least biochemically into the tauren ii class as opposed to the rapamycin class”

“which is interesting because this wasn't a rap ayon right it was one of these ATP competitive mtor Inhibitors but I think it's still a little bit clear if the drug itself actually failed to have an have an impact on immune function in in the population where it was tested but it but it was a very dirty catalytic inhibitor right it it impacts multiple pi3 kinases so absolutely yeah and I mean that makes it harder from the perspective of even if it did have an impact how is it working is it really through mtor is it through some of these other kinases is it a combination yeah we don't we don't really we don't really know cuz it is dirty”

“and rtb 101 which we didn't talk about the future the subsequent studies from Joan at novaris and then when when she went on to restore bio there's this another molecule rtb 101 that I think would fall into these ATP competitive mtor inhibitor class but it also inhibits other kinases so the specificity for some of these molecules is less”